| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
TG Therapeutics Inc (NASDAQ: TGTX)
TGTX Technical Analysis
5
| As on 1st Aug 2025 TGTX STOCK Price closed @ 35.02 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 21.59 & Strong Buy for SHORT-TERM with Stoploss of 14.98 we also expect STOCK to react on Following IMPORTANT LEVELS. |
TGTXSTOCK Price
| Open | 34.89 | Change | Price | % |
| High | 35.75 | 1 Day | -0.48 | -1.35 |
| Low | 34.03 | 1 Week | -2.58 | -6.86 |
| Close | 35.02 | 1 Month | -0.14 | -0.40 |
| Volume | 2317464 | 1 Year | 20.83 | 146.79 |
| 52 Week High 45.51 | 52 Week Low 13.02 | ||||
NASDAQ USA Most Active Stocks
| AMRS | 0.14 | 100.00% |
| NVDA | 173.72 | -2.33% |
| OPEN | 2.10 | 14.13% |
| EQ | 0.71 | 82.05% |
| AMZN | 214.75 | -8.27% |
| NCNA | 0.04 | 0.00% |
| LMDX | 0.02 | 0.00% |
| BTAI | 1.37 | 4.58% |
| AKTS | 0.04 | 0.00% |
| AAPL | 202.38 | -2.50% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| TGTX Daily Charts |
TGTX Intraday Charts |
Whats New @ Bazaartrend |
TGTX Free Analysis |
|
|
TGTX Important Levels Intraday
| RESISTANCE | 38.33 |
| RESISTANCE | 37.27 |
| RESISTANCE | 36.61 |
| RESISTANCE | 35.96 |
| SUPPORT | 34.08 |
| SUPPORT | 33.43 |
| SUPPORT | 32.77 |
| SUPPORT | 31.71 |
TGTX Forecast August 2025
| 4th UP Forecast | 46.93 |
| 3rd UP Forecast | 43.11 |
| 2nd UP Forecast | 40.75 |
| 1st UP Forecast | 38.39 |
| 1st DOWN Forecast | 31.65 |
| 2nd DOWN Forecast | 29.29 |
| 3rd DOWN Forecast | 26.93 |
| 4th DOWN Forecast | 23.11 |
TGTX Weekly Forecast
| 4th UP Forecast | 46.56 |
| 3rd UP Forecast | 42.86 |
| 2nd UP Forecast | 40.57 |
| 1st UP Forecast | 38.28 |
| 1st DOWN Forecast | 31.76 |
| 2nd DOWN Forecast | 29.47 |
| 3rd DOWN Forecast | 27.18 |
| 4th DOWN Forecast | 23.48 |
TGTX Forecast2025
| 4th UP Forecast | 99.84 |
| 3rd UP Forecast | 79.05 |
| 2nd UP Forecast | 66.2 |
| 1st UP Forecast | 53.35 |
| 1st DOWN Forecast | 16.69 |
| 2nd DOWN Forecast | 3.84 |
| 3rd DOWN Forecast | -9.01 |
| 4th DOWN Forecast | -29.8 |
TG Therapeutics Inc ( NASDAQ USA Symbol : TGTX )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
TGTX Business Profile
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. The company is headquartered in New York, New York. Address: 2 Gansevoort Street, New York, NY, United States, 10014
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service